Peptides and peptide conjugates: Therapeutics on the upward path

Future Medicinal Chemistry

Volumn 4, Issue 12, 2012, Pages 1567-1586

  Ahrens, Verena M ^a   Bellmann Sickert, Kathrin ^a   Beck Sickinger, Annette G ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ASPARAGINASE MACROGOL; BLEOMYCIN; CERTOLIZUMAB PEGOL; CETRORELIX; CJC 1134 PC; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CORTICOTROPIN; CYCLOSPORIN; DAPTOMYCIN; DESMOPRESSIN; ENFUVIRTIDE; EPTIFIBATIDE; EXENDIN 4; FELYPRESSIN; GLUCAGON; GOSERELIN; GRAMICIDIN D; HESYLATION; HIRULOG; ICATIBANT; INSULIN; INSULIN DETEMIR; LEPIRUDIN; LEUPRORELIN; OCTREOTIDE; OXYTOCIN; PASYLATION; PEGADEMASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGLOTICASE; PEGVISOMANT; PENTETREOTIDE; PEPTIDE DERIVATIVE; PRAMLINTIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT SOMATOMEDIN C; SALCATONIN; SERMORELIN; TESAMORELIN; TETRACOSACTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

DRUG ACTIVITY; DRUG CONJUGATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG CARRIERS; HUMANS; PEPTIDES; PROTEIN INTERACTION MAPS; PROTEIN STABILITY;

EID: 84865470622     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.76     Document Type: Review

References (105)

1. US FDA. Approved Drug Products with Therapeutic Equivalence Evaluation. Division of Drug Information, Silver Spring, MD, USA, 31 (2011).
2. Gambacorti-Passerini C. Part I: Milestones in personalised medicine - imatinib. Lancet Oncol. 9(6), 600 (2008). (Pubitemid 351722585)
3. Marx V. Watching peptide drugs grow up. Chem. Eng. News 83(11), 17-24 (2005). (Pubitemid 40402233)
4. Itakura K, Hirose T, Crea R et al. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science 198(4321), 1056-1063 (1977). (Pubitemid 8239006)
5. Crea R, Kraszewski A, Hirose T, Itakura K. Chemical synthesis of genes for human insulin. Proc. Natl Acad. Sci. USA 75(12), 5765-5769 (1978). (Pubitemid 9099005)
6. Goeddel DV, Kleid DG, Bolivar F et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl Acad. Sci. USA 76(1), 106-110 (1979).
7. du Vigneaud V, Ressler C, Swan JM, Katsoyannis PG, Roberts CW. The synthesis of an octapeptide amide with the hormonal acitivity of oxytocin. J. Am. Chem. Soc. 75(19), 4879-4880 (1953).
8. Göhring W, Gokhale S, Hilpert H et al. Synthesis of the HIV-proteinase inhibitor saquinavir: a challenger for process research. Chimia 50(11), 532-537 (1996).
9. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85(14), 2149-2154 (1963).
10. Dawson PE, Muir TW, Clark-Lewis I, Kent SB. Synthesis of proteins by native chemical ligation. Science 266(5186), 776-779 (1994). (Pubitemid 24359280)
11. David R, Richter MP, Beck-Sickinger AG. Expressed protein ligation. Method and applications. Eur. J. Biochem. 271(4), 663-677 (2004). (Pubitemid 38250909)
12. Pattabiraman VR, Bode JW. Rethinking amide bond synthesis. Nature 480(7378), 471-479 (2011).
13. Marx V. Roche's Fuzeon challenge. Chem. Eng. News 83(11), 16-17 (2005).
14. McGregor DP. Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol. 8(5), 616-619 (2008).
15. Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2(7), 587-593 (2003). (Pubitemid 37361750)
16. Schmidt MC, Rothen-Rutishauser B, Rist B et al. Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane. Biochemistry 37(47), 16582-16590 (1998). (Pubitemid 28543917)
17. Rennert R, Neundorf I, Beck-Sickinger AG. Calcitonin-derived peptide carriers: mechanisms and application. Adv. Drug Deliv. Rev. 60(4-5), 485-498 (2008).
18. Khafagyel S, Morishita M, Isowa K, Imai J, Takayama K. Effect of cell-penetrating peptides on the nasal absorption of insulin. J. Control. Release 133(2), 103-108 (2009).
19. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev. 61(13), 1177-1188 (2009).
20. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252(11), 3578-3581 (1977). (Pubitemid 8116087)
21. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252(11), 3582-3586 (1977). (Pubitemid 8116088)
22. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10(21), 1451-1458 (2005). (Pubitemid 41483874)
23. Alconcel SNS, Baas AS, Maynard HD. FDA-aproved poly (ethylene glycol)-protein conjugate drugs. Polymer Chem. 2(7), 1442-1448 (2011).
24. Noberini R, Mitra S, Salvucci O et al. PEGylation potentiates the effectiveness of an antagonistic Ppeptide that targets the EphB4 receptor with nanomolar affinity. PLoS ONE 6(12), e28611 (2011).
25. Mezo AR, Low SC, Hoehn T, Palmieri H. PEGylation enhances the therapeutic potential of peptide antagonists of the neonatal Fc receptor, FcRn. Bioorg. Med. Chem. Lett. 21(21), 6332-6335 (2011).
26. Kurtzhals P, Havelund S, Jonassen I et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligandprotein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312(Pt 3), 725-731 (1995). (Pubitemid 26005980)
27. Bellmann-Sickert K, Elling CE, Madsen AN et al. Long-acting lipidated analogue of human pancreatic polypeptide is slowly released into circulation. J. Med. Chem. 54(8), 2658-2667 (2011).
28. Larsen BD, Jensen LH, Mork NE et al. Structural inducing probes (SIP) - blows new hope into the general use of peptides as drugs. Presented at: 26th European Peptide Symposium. Montpellier, France, 10-15 September 2001.
29. Milton RC, Milton SC, Kent SB. Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity. Science 256(5062), 1445-1448 (1992).
30. Tugyi R, Uray K, Ivan D et al. Partial d-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc. Natl Acad. Sci. USA 102(2), 413-418 (2005). (Pubitemid 40116781)
31. Rennert R, Wespe C, Beck-Sickinger AG, Neundorf I. Developing novel hCT derived cell-penetrating peptides with improved metabolic stability. Biochim. Biophys. Acta 1758(3), 347-354 (2006).
32. Rink R, Arkema-Meter A, Baudoin I et al. To protect peptide pharmaceuticals against peptidases. J. Pharmacol. Toxicol. Methods 61(2), 210-218 (2010).
33. Bläuenstein P, Garayoa EG, Ruegg D et al. Improving the tumor uptake of 99mTclabeled neuropeptides using stabilized peptide analogues. Cancer Biother. Radiopharm. 19(2), 181-188 (2004). (Pubitemid 38685116)
34. Wiegand H, Wirz B, Schweitzer A et al. The outstanding metabolic stability of a 14C-labeled b-nonapeptide in rats - in vitro and in vivo pharmacokinetic studies. Biopharm. Drug Dispos. 23(6), 251-262 (2002).
35. Wang Y, Lin H, Tullman R et al. Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. Biopharm. Drug Dispos. 20(2), 69-75 (1999). (Pubitemid 29082199)
36. Lugrin D, Vecchini F, Doulut S et al. Reduced peptide bond pseudopeptide analogues of neurotensin: binding and biological activities, and in vitro metabolic stability. Eur. J. Pharmacol. 205(2), 191-198 (1991).
37. Binder U, Skerra A. Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics In: Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives. Kontermann RE (Ed.). Wiley-VCH, Weinheim, Germany, 63-80 (2012).
38. Hey T, Knoller H, Vorstheim P. Half-life extension through HESylation. In: Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives. Kontermann RE (Ed.). Wiley-VCH, Weinheim, Germany, 117-141 (2012).
39. Besheer A, Hertel TC, Kressler J, Mader K, Pietzsch M. Enzymatically catalyzed conjugation of a biodegradable polymer to proteins and small molecules using microbial transglutaminase. Methods Mol. Biol. 751, 17-27 (2011).
40. Besheer A, Hertel TC, Kressler J, Mader K, Pietzsch M. Enzymatically catalyzed HES conjugation using microbial transglutaminase: Proof of feasibility. J. Pharm. Sci. 98(11), 4420-4428 (2009).
41. Noga M, Edinger D, Rodl W et al. Controlled shielding and deshielding of gene delivery polyplexes using hydroxyethyl starch (HES) and α-amylase. J. Control. Release 159(1), 92-103 (2012).
42. Knox C, Law V, Jewison T et al. DrugBank 3.0: a comprehensive resource for omics' research on drugs. Nucleic Acids Res. 39(Database issue), D1035-D1041 (2011).
43. Wang F, Qin L, Pace CJ et al. Solubilized gramicidin a as potential systemic antibiotics. Chembiochem 13(1), 51-55 (2012).
44. Hawkey PM. Pre-clinical experience with daptomycin. J. Antimicrob. Chemother. 62(Suppl. 3), III7-III14 (2008).
45. Tan O, Bukulmez O. Biochemistry, molecular biology and cell biology of gonadotropinreleasing hormone antagonists. Curr. Opin. Obstet. Gynecol. 23(4), 238-244 (2011).
46. Reissmann T, Schally AV, Bouchard P, Riethmiiller H, Engel J. The LHRH antagonist cetrorelix: a review. Hum. Reprod. Update 6(4), 322-331 (2000). (Pubitemid 30657786)
47. Van Poppel H, Klotz L. Gonadotropinreleasing hormone: an update review of the antagonists versus agonists. Int. J. Urol. (2012).
48. Lepor H. The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev. Urol. 8(4), 183-189 (2006).
49. Gosselin RC, Dager WE, King JH et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am. J. Clin. Pathol. 121(4), 593-599 (2004). (Pubitemid 38392969)
50. Greig NH, Holloway HW, De Ore KA et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42(1), 45-50 (1999).
51. Madsbad S, Kielgast U, Asmar M et al. An overview of once-weekly glucagon-like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes. Metab. 13(5), 394-407 (2011).
52. De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays 26(12), 1351-1362 (2004). (Pubitemid 39664629)
53. Este JA, Telenti A. HIV entry inhibitors. Lancet 370(9581), 81-88 (2007). (Pubitemid 47018315)
54. Furuta RA, Wild CT, Weng Y, Weiss CD. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5(4), 276-279 (1998). (Pubitemid 28164878)
55. Carlsen SM, Svartberg J, Schreiner T et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin. Endocrinol. (Oxf.) 74(6), 736-743 (2011).
56. Saladin PM, Zhang BD, Reichert JM. Current trends in the clinical development of peptide therapeutics. IDrugs 12(12), 779-784 (2009).
57. Bunnage ME. Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7(6), 335-339 (2011). Discusses the recent challenges pharmaceutical industry is facing in terms of approved new molecular entities and how this could be changed by improved target selection.
58. Mullard A. 2011 FDA drug approvals. Nat. Rev. Drug Discov. 11(2), 91-94 (2012).
59. Baba T, Sato-Matsushita M, Kanamoto A et al. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. J. Transl. Med. 8, 84 (2010).
60. Kyte JA, Gaudernack G, Dueland S et al. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin. Cancer Res. 17(13), 4568-4580 (2011).
61. Holmes JP, Benavides LC, Gates JD et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J. Clin. Oncol. 26(20), 3426-3433 (2008).
62. Carmichael MG, Benavides LC, Holmes JP et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 116(2), 292-301 (2010).
63. Miyazawa M, Ohsawa R, Tsunoda T et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 101(2), 433-439 (2010).
64. Miyazaki A, Kobayashi J, Torigoe T et al. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci. 102(2), 324-329 (2011).
65. Kitawaki T, Kadowaki N, Fukunaga K et al. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. Br. J. Haematol. 153(6), 796-799 (2011).
66. Dechantsreiter MA, Planker E, Matha B et al. N-Methylated cyclic RGD peptides as highly active and selective a (V) b (3) integrin antagonists. J. Med. Chem. 42(16), 3033-3040 (1999). (Pubitemid 29384038)
67. Tabatabai G, Weller M, Nabors B et al. Targeting integrins in malignant glioma. Target Oncol. 5(3), 175-181 (2010).
68. Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(16), 2712-2718 (2010).
69. Sato N, Ogino Y, Mashiko S, Ando M. Modulation of neuropeptide Y receptors for the treatment of obesity. Expert Opin. Ther. Pat. 19(10), 1401-1415 (2009).
70. Smith SR, Aronne LJ, Burns CM et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 31(9), 1816-1823 (2008).
71. Bellmann-Sickert K, Beck-Sickinger AG. Peptide drugs to target G protein-coupled receptors. Trends Pharmacol. Sci. 31(9), 434-441 (2010). Focuses on peptidic therapeutics targeting GPCR mainly targeting the immune system, endocrine functions in modulating food intake and cancer.
72. Chollet C, Meyer K, Beck-Sickinger AG. Ghrelin - a novel generation of anti-obesity drug: design, pharmacomodulation and biological activity of ghrelin analogues. J. Pept. Sci. 15(11), 711-730 (2009).
73. Holst B, Lang M, Brandt E et al. Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. Mol. Pharmacol. 70(3), 936-946 (2006). (Pubitemid 44268450)
74. Walther C, Mörl K, Beck-Sickinger AG. Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development. J. Pept. Sci. 17(4), 233-246 (2011).
75. Miller LJ, Gao F. Structural basis of cholecystokinin receptor binding and regulation. Pharmacol. Ther. 119(1), 83-95 (2008).
76. Washington MC, Coggeshall J, Sayegh AI. Cholecystokinin-33 inhibits meal size and prolongs the subsequent intermeal interval. Peptides 32(5), 971-977 (2011).
77. Söll RM, Dinger MC, Lundell I, Larhammer D, Beck-Sickinger AG. Novel analogues of neuropeptide Y with a preference for the Y1-receptor. Eur. J. Biochem. 268(10), 2828-2837 (2001). (Pubitemid 32862965)
78. Khan IU, Zwanziger D, Böhme I et al. Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application. Angew. Chem. Int. Ed. Engl. 49(6), 1155-1158 (2010). The synthesis of a 99mTc-labeled breast tumor targeting peptide is described including in vitro testing, in vivo testing in rabbits and studies on peptide uptake in human breast cancer patients.
79. Ahrens VM, Frank R, Stadlbauer S, Beck-Sickinger AG, Hey-Hawkins E. Incorporation of ortho-carbaboranyl-Nepsilon-modified l-lysine into neuropeptide Y receptor Y1-and Y2-selective analogues. J. Med. Chem. 54(7), 2368-2377 (2011).
80. Craft JM, De Silva RA, Lears KA et al. In vitro and in vivo evaluation of a (64) Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer. Nucl. Med. Biol. 39(5), 606-616 (2012).
81. Hatakeyama S, Sugihara K, Shibata TK et al. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide. Proc. Natl Acad. Sci. USA 108(49), 19587-19592 (2011).
82. Leriche G, Chisholm L, Wagner A. Cleavable linkers in chemical biology. Bioorg. Med. Chem. 20(2), 571-582 (2012). Describes the application of seven different types of cleavable linkers in chemical biology. Unfortunately, not all of them are compatible with biological systems and drug design.
83. Gillies ER, Goodwin AP, Frechet JM. Acetals as pH-sensitive linkages for drug delivery. Bioconjug. Chem. 15(6), 1254-1263 (2004). (Pubitemid 39552014)
84. Schlossbauer A, Dohmen C, Schaffert D, Wagner E, Bein T. pH-responsive release of acetal-linked melittin from SBA-15 mesoporous silica. Angew. Chem. Int. Ed. Engl. 50(30), 6828-6830 (2011).
85. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc. Natl Acad. Sci. USA 103(37), 13872-13877 (2006). (Pubitemid 44414000)
86. Vlahov IR, Wang Y, Kleindl PJ, Leamon CP. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part II: Folic acid conjugates of tubulysins and their hydrazides. Bioorg. Med. Chem. Lett. 18(16), 4558-4561 (2008).
87. Leamon CP, Reddy JA, Vetzel M et al. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res. 68(23), 9839-9844 (2008).
88. Reddy JA, Dorton R, Dawson A et al. In vivo structural activity and optimization studies of folate-tubulysin conjugates. Mol. Pharm. 6(5), 1518-1525 (2009).
89. Liu Z, Chen K, Davis C et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 68(16), 6652-6660 (2008).
90. Langer M, Kratz F, Rothen-Rutishauser B, Wunderli-Allenspach H, Beck-Sickinger AG. Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem. 44(9), 1341-1348 (2001). (Pubitemid 32852109)
91. Matson JB, Stupp SI. Drug release from hydrazone-containing peptide amphiphiles. Chem. Commun. (Camb.) 47(28), 7962-7964 (2011).
92. Splith K, Hu W, Schatzschneider U et al. Protease-activatable organometal-peptide bioconjugates with enhanced cytotoxicity on cancer cells. Bioconjug. Chem. 21(7), 1288-1296 (2010).
93. Doronina SO, Toki BE, Torgov MY et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21(7), 778-784 (2003). (Pubitemid 36791396)
94. Doronina SO, Bovee TD, Meyer DW et al. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug. Chem. 19(10), 1960-1963 (2008).
95. Hajdin K, D'Alessandro V, Niggli FK, Schafer BW, Bernasconi M. Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model. PLoS ONE 5(5), e10445 (2010).
96. Diez-Torrubia A, Garcia-Aparicio C, Cabrera S et al. Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs. J. Med. Chem. 53(2), 559-572 (2010).
97. Diez-Torrubia A, Balzarini J, Andrei G et al. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues. J. Med. Chem. 54(6), 1927-1942 (2011).
98. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov. Today 15(1-2), 40-56 (2010)
99. Skerra A, Theobald I, Schlapschy M. Biological active proteins having increased in vivo and/or in vitro stability. EP2173890 (2008).
100. Zander N, Eichner W, Conradt HS et al. Conjugates of hydroxalkyl starch and a protein, prepared by reductive amination. EP2336192 (2011).
101. Eichner W, Knoller H, Lutterbeck K et al. Conjugates of hydroxyalkyl starch and G-CSF. IP1660134 (2010)
102. XL-protein GmbH. www.xl-protein.com/technology.html
103. ClinicalTrials.gov. www.clinicaltrials.gov
104. Simons J, How the Exubera debacle hurts Pfizer. CNN Money. http://money.cnn. com/2007/10/19/magazines/fortune/simons-pfizer-erbitux. fortune/index.htm
105. TM Pharma. www.7tm.dk/R-D/Metabolic-Disorders.aspx